Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

SHA:603229 Revenue

Zhejiang Ausun Pharmaceutical had revenue of 158.94M CNY in the quarter ending June 30, 2026, a decrease of -9.30%. This brings the company's total for the last twelve months to 778.50M, down -0.80% year-over-year. In the year 2025, Zhejiang Ausun Pharmaceutical had annual revenue of 792.76M, down -0.32%. That makes Zhejiang Ausun Pharmaceutical the 21,486th largest company in the world by revenue and 3,941st in China.

• Revenue (ttm): 778.50M
• Revenue Growth: -0.80%
• P/S Ratio: 7.82
• Revenue / Employee: 586.22K
• Employees: 1,328
• Market Cap: 6.09B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Raw Materials and Intermediates 754.04M 95.1%
• Fees for Technical Services 36.83M 4.6%
• Pharmaceutical Preparation 1.89M 0.2%

By Geography

Chart

• Overseas 500.10M 63.1%
• China 292.66M 36.9%

Fiscal year ended Dec 31, 2025 See the full SHA:603229 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	792.76M	-2.53M	-0.32%
Dec 31, 2024	795.29M	-21.48M	-2.63%
Dec 31, 2023	816.77M	52.22M	6.83%
Dec 31, 2022	764.55M	194.85M	34.20%
Dec 31, 2021	569.70M	160.45M	39.21%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 20, 2026

Data Sources Report a data error